• Biological – A novel long acting GLP-1(glucagon-like peptide-1) receptor agonist

• GLP-1 receptor activation may have a potential therapeutic application as a treatment for diseases that involve muscle atrophy and muscle wasting.
  (Ref: Hong et el., 2019)
• Elastin-Like Polypeptide (ELP) half-life extension technology platform enables once weekly injection
• Safety profile based on clinical data from phase 2b study in type 2 diabetes (20 weeks)

• Drug re-positioning global development strategy :

  Targeting various indications involved in muscle atrophy including DMD, BMDand Polymyositis

• Stage :

  IND submission for phase IIa in DMD

• DMD and BMD are genetic disorders characterized by the progressive loss of muscle

Symptoms

• Difficulty rising from a lying or sitting position
• Large calf muscle, Walking on toes
• BMD is a milder version of DMD

Causes

• the mutated DMD gene fails to produce virtually any functional dystrophin
• BMD genetic mutations make partially functional dystrophin

Standard Therapy

• High dose glucocorticoids

• A rare, idiopathic, inflammatory myopathy

Symptoms

• Symmetric proximal muscle weakness
• In severe cases, causes dysphagia or dysphonia
• Serious threat to the quality of daily life

Causes

• Auto-immune responses in skeletal muscle
• Lymphocyte infiltration in the muscle

Standard Therapy

• High dose glucocorticoids
• Glucocorticoid-induced toxicity

• A complex disease with degenerative pathological mechanisms as well as autoimmune mediated by T lymphocytes

Symptoms

• Progressive muscle weakness in distal finger flexor muscles and the quadriceps
• Unlike other myositis, asymmetric and distal muscle weakness are likely to appear with slow disease progression

Causes

• Inflammatory cells invade the muscle tissue and concentrate between the muscle fibers presenting multiple inclusion bodies that contain cellular material of dead tissue.

Standard Therapy

• Immunosuppressant drugs
• Corticosteroid doesn’t work for IBM.

• Senile sarcopenia is the loss of muscle mass due to the natural aging process

Symptoms

• Loss of lean muscle mass and decreased muscle size
• Reduced strength, functional decline and increased risk of falling

Causes

• Senile sarcopenia is likely the result of multiple interacting factors such as changes in hormones, age-related muscle changes, nutrition, and lifestyle

Standard Therapy

• Currently there are no medication to treat senile sarcopenia

BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate

BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate

BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate

• Indication
  : ALS (Amyotrophic lateral sclerosis)
  (also known as Lou Gehrig's disease Or motor neurone disease)
• ALS
  : ALS is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 3-5 years after disease onset.
• Class
  : Biologics, Dual ligand Fc fusion protein
• Global market size expectation : USD 800 million in 2026
• Status : in vivo PK
• Next plan : in vivo Efficacy test

Indication: Degenerative arthritis

• Class: First-in-class new biologic drug: dual function fusion protein
• Most common degenerative joint disease with extreme pain from joint cartilage destruction or regression
• Global market: $ 6 billion in 2019 → $ 9 billion in 2024 (CAGR: 8.1%)
• Novel Disease-modifying osteoarthritis drug (DMOAD)
• Status: Stable cell line development